Gene Solutions, a prominent player in genetic testing in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences) to inaugurate an advanced genomics laboratory in Hyderabad on October 1, 2025. This collaboration aims to enhance access to precision medicine through the introduction of next-generation sequencing (NGS) technologies, making advanced diagnostics more accessible to patients and healthcare providers throughout India.
The new laboratory is set to leverage AMPATH’s extensive diagnostic network, which includes over 20 satellite laboratories and more than 2,000 collection points. This infrastructure will facilitate the integration of genomic testing into routine healthcare practices. The facility in Hyderabad will provide several advanced services, including:
– **triSure NIPT**: A non-invasive prenatal testing solution offering insights into chromosomal conditions and select genetic disorders, ensuring expectant parents have early and safe options for assessing fetal health.
– **SPOT-MAS**: A clinically validated cancer screening tool capable of detecting signals from 75 cancer types using a single blood sample, aiding early intervention strategies.
– **K-TRACK** and **K-4CARE**: Comprehensive cancer monitoring and genomic profiling solutions that empower physicians to personalize treatment plans and effectively monitor recurrence.
Enhancing Patient Care through Innovative Diagnostics
The partnership between Gene Solutions and AMPATH signifies a commitment to improving patient outcomes through advanced genomic testing. By offering state-of-the-art diagnostic tools, the collaboration facilitates:
– More informative prenatal screenings, granting parents timely insights into fetal health and maternal conditions.
– Earlier cancer detection, allowing healthcare providers to identify critical signals from common cancers, including breast and lung cancer, through simple blood tests.
– Personalized cancer care, helping oncologists tailor treatments according to individual patient needs using cutting-edge genomic technologies.
“This partnership reflects a shared vision—making high-quality, science-driven genetic testing more widely available,” stated Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions. He emphasized the importance of inclusivity in technology, noting that collaboration with AMPATH enables the delivery of advanced solutions within a trusted healthcare framework.
In agreement, Dr. Maneesh Bagai, COO of AMPATH, highlighted the significance of this strategic alliance, stating, “Together, we are redefining what’s possible in diagnostics—whether it’s in maternal health, early cancer detection, or personalized oncology with a patient-centric approach.”
About the Organizations
AMPATH is recognized as a leader in pathology services in India, known for its adherence to international standards and excellence in clinical diagnostics. Headquartered in Hyderabad, AMPATH operates a Central Reference Laboratory and a network of over 20 satellite labs nationwide, supported by accreditation from the National Accreditation Board for Testing & Calibration Laboratories (NABL). As part of CTSI South Asia, AMPATH also operates the American Oncology Institute (AOI) and a network of specialty hospitals, reinforcing its dedication to precision medicine and personalized treatment strategies.
Gene Solutions is a multinational biotechnology firm at the forefront of genetic testing and research innovation across the Asia-Pacific region. Utilizing NGS and artificial intelligence, the company provides a range of services, including non-invasive prenatal testing, cancer screening via circulating tumor DNA, genomic profiling, and treatment monitoring. With a history of delivering over two million genetic tests, Gene Solutions is committed to advancing precision medicine through technological innovation and regional collaboration.
The launch of this advanced genomics laboratory represents a significant step forward in enhancing healthcare capabilities in India, ensuring that more individuals can benefit from cutting-edge diagnostic technologies.
